New allergy drug shows promise in early trial
NCT ID NCT03570957
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This early-stage study tested a single dose of MT-2990 in 75 adults with seasonal allergic rhinitis from Japanese cedar pollen. The goal was to check safety, how the drug moves through the body, and its effect on allergy symptoms in a controlled pollen exposure chamber. Participants were followed for several months to monitor side effects and symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.